Factors influencing HER2 positivity in breast cancer according to statistical modeling and data mining techniques based on a real-world national database: HER-France.
E12086 Background: HER-France is a national database collecting information on HER2 status in invasive breast cancer supplied by 124 French pathology labs (FPL). It is conducted by the French Association for Quality Control in Histopathology (AFAQAP) since October 2011. Its goal is to follow the national HER2 rate and its change over time. An analysis of this database was carried in October 2015 on 105,717 records to search for factors associated with HER2 positivity. Methods: To identify these factors, multivariate regression models were applied, as well as supervised and unsupervised Data Mining techniques such as Bayesian Networks and Decision trees were used to represent dependencies between tumor characteristics and HER2 positivity. HER2 status was determined by immunohistochemistry and in situ hybridization using ASCO/CAP 2013 guidelines. To avoid bias due to adverse pre-analytic conditions, only results on Core-Biopsies (CB) are presented hereafter. Results: Out of 105,717 records, 45,785 (43.3%) CB were analyzed. 41,586 (90.8%) CB were evaluable for HER2 status and 4,976 (12.0%) were HER2+. Factors influencing HER2 positivity were No Special Type histologic subtype (OR=2.27, 95%CI [1.89-2.77]), high histologic grade (OR=4.71, 95%CI [3.86-5.76]), negative or low hormonal receptor status (OR=1.85, 95%CI [1.67-2.04]), and higher Ki67 index (OR=3.06, 95%CI [2.72-3.44]). Bayesian Network confirmed the importance of these parameters, providing thresholds linked to high HER2 positivity rates, as shown in table below. Conclusions: HER-France is a nationwide database showing 12.0% of HER2+ on breast cancer CB between 2011 and 2015. Histological subtype, grade and ER-PR status as reported in the German database study (Ruschoff et al.), but also Ki67 are factors influencing HER2 positivity. In the future, these results should be integrated to develop new HER-France functionalities in order to allow FPL to compare their actual HER2 rate to the expected HER2 rate based on these factors.